New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 20, 2014
07:56 EDTLCILannett digoxen use in clinics unlikely to change, says Canaccord
Canaccord said the use of Lannett's digoxen drug was only prescribed to critically ill Afib patients so the mortality risk cited in a retrospective study by Turakhia is not surprising. Given the risk of thrombotic events from Afib progression far outweighing the mortality risk the firm sees little change to clinical practice. Shares of Lannett are Buy rated with a $55 price target.
News For LCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
14:29 EDTLCILannett announces FDA approval of Letrozole tablets
Subscribe for More Information
October 23, 2014
07:56 EDTLCILannett sees Q1 EPS 91c-94c, consensus 77c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use